N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency

Current Opinion in Pharmacology

Volumn 7, Issue 4, 2007, Pages 355-359

  Atkuri, Kondala R ^a   Mantovani, John J ^a   Herzenberg, Leonard A ^a   Herzenberg, Leonore A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIDOTE; CATALASE; CYSTEINE; FREE RADICAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LACTOSE; PARACETAMOL; PLACEBO; REACTIVE OXYGEN METABOLITE; STEROID; SUPEROXIDE DISMUTASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; AMINO ACID DEFICIENCY; ANAPHYLAXIS; ANTIOXIDANT ACTIVITY; BRONCHITIS; CARDIOVASCULAR DISEASE; CELL DAMAGE; CELL STRESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLON CANCER; CYSTIC FIBROSIS; DETOXIFICATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG INDICATION; DRUG INTOXICATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; EFFERVESCENT TABLET; FIRST PASS EFFECT; GENETIC DISORDER; GOOD MANUFACTURING PRACTICE; HEARTBURN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; INHIBITION KINETICS; LIVER TOXICITY; METABOLIC DISORDER; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; QUALITY OF LIFE; REVIEW; STOMACH DISEASE; TREATMENT OUTCOME; URTICARIA; VOMITING; WELLBEING;

ACETAMINOPHEN; ACETYLCYSTEINE; ANTIDOTES; CONTROLLED CLINICAL TRIALS; CYSTEINE; CYSTIC FIBROSIS; FREE RADICAL SCAVENGERS; GLUTATHIONE; HIV INFECTIONS; HUMANS; PRODRUGS; QUALITY OF LIFE;

EID: 34548072307     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.04.005     Document Type: Review

References (45)

1. Schafer F.Q., and Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30 (2001) 1191-1212
2. Halliwell B. Antioxidants in human health and disease. Annu Rev Nutr 16 (1996) 33-50
3. Prescott L. Oral or intravenous N-acetylcysteine for acetaminophen poisoning?. Ann Emerg Med 45 (2005) 409-413. This paper provides a clear summary of current clinical views on N-acetylcysteine treatment for acetaminophen poisoning.
4. Breitkreutz R., Pittack N., Nebe C.T., Schuster D., Brust J., Beichert M., Hack V., Daniel V., Edler L., and Droge W. Improvement of immune functions in HIV infection by sulfur supplementation: two randomized trials. J Mol Med 78 (2000) 55-62
5. De Rosa S.C., Zaretsky M.D., Dubs J.G., Roederer M., Anderson M., Green A., Mitra D., Watanabe N., Nakamura H., Tjioe I., et al. N-Acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 30 (2000) 915-929
6. Ratjen F., Wonne R., Posselt H.G., Stover B., Hofmann D., and Bender S.W. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr 144 (1985) 374-378
7. Tirouvanziam R., Conrad C.K., Bottiglieri T., Herzenberg L.A., Moss R.B., and Herzenberg L.A. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 103 (2006) 4628-4633. This paper illustrates the safety and efficacy of high-dose oral NAC treatment in patients with cystic fibrosis, who suffer from chronic inflammation and oxidative stress, often complicated by intestinal malabsorption and liver dysfunction. Systemic NAC improves several markers of cystic fibrosis lung inflammation.
8. Kasielski M., and Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 95 (2001) 448-456
9. De Mattia G., Bravi M.C., Laurenti O., Cassone-Faldetta M., Armiento A., Ferri C., and Balsano F. Influence of reduced glutathione infusion on glucose metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 47 (1998) 993-997
10. Aitio M.L. N-Acetylcysteine-passe-partout or much ado about nothing?. Br J Clin Pharmacol 61 (2006) 5-15. This is one of the most comprehensive critical review of placebo-controlled clinical trials with NAC. This review also provides a summary of several important in vitro and animal studies with N-acetylcysteine.
11. Grandjean E.M., Berthet P., Ruffmann R., and Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 22 (2000) 209-221
12. Zagler A., Azadpour M., Mercado C., and Hennekens C.H. N-Acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J 151 (2006) 140-145
13. Liu R., Nair D., Ix J., Moore D.H., and Bent S. N-Acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med 20 (2005) 193-200
14. Stey C., Steurer J., Bachmann S., Medici T.C., and Tramer M.R. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review [In Process Citation]. Eur Respir J 16 (2000) 253-262
15. Zafarullah M., Li W.Q., Sylvester J., and Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60 (2003) 6-20
16. Ziment I. Acetylcysteine: a drug that is much more than a mucokinetic. Biomed Pharmacother 42 (1988) 513-519
17. Harada D., Anraku M., Fukuda H., Naito S., Harada K., Suenaga A., and Otagiri M. Kinetic studies of covalent binding between N-acetyl-l-cysteine and human serum albumin through a mixed-disulfide using an N-methylpyridinium polymer-based column. Drug Metab Pharmacokinet 19 (2004) 297-302
18. Aruoma O.I., Halliwell B., Hoey B.M., and Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 6 (1989) 593-597
19. Koh A.S., Simmons-Willis T.A., Pritchard J.B., Grassl S.M., and Ballatori N. Identification of a mechanism by which the methylmercury antidotes N-acetylcysteine and dimercaptopropanesulfonate enhance urinary metal excretion: transport by the renal organic anion transporter-1. Mol Pharmacol 62 (2002) 921-926
20. Bonanomi L., and Gazzaniga A. Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. Eur J Respir Dis Suppl 111 (1980) 45-51
21. Jones C.M., Lawrence A., Wardman P., and Burkitt M.J. Kinetics of superoxide scavenging by glutathione: an evaluation of its role in the removal of mitochondrial superoxide. Biochem Soc Trans 31 (2003) 1337-1339
22. Holdiness M.R. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet 20 (1991) 123-134
23. Cotgreave I.A. N-Acetylcysteine: pharmacological considerations and experimental and clinical applications. In: Sies H. (Ed). Advances in Pharmacology, vol 38: Antioxidants in Disease Mechanisms and Therapy (1997), Academic Press Inc. 205-227
24. Bridgeman M.M.E., Marsden M., Macnee W., Flenley D.C., and Ryle A.P. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax 46 (1991) 39-42
25. Noszal B., Visky D., and Kraszni M. Population, acid-base, and redox properties of N-acetylcysteine conformers. J Med Chem 43 (2000) 2176-2182
26. Griffith O.W., and Meister A. Glutathione: interorgan translocation, turnover, and metabolism. Proc Natl Acad Sci USA 76 (1979) 5606-5610
27. Sarnstrand B., Jansson A.H., Matuseviciene G., Scheynius A., Pierrou S., and Bergstrand H. N,N′-Diacetyl-l-cystine - the disulfide dimer of N-acetylcysteine - is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents. J Pharmacol Exp Ther 288 (1999) 1174-1184
28. van de Poll M.C., Dejong C.H., and Soeters P.B. Adequate range for sulfur-containing amino acids and biomarkers for their excess: lessons from enteral and parenteral nutrition. J Nutr 136 (2006) 1694S-1700S. This paper provides a comprehensive review of biochemistry, nutritional value and biomarkers for sulfur-containing amino acids.
29. Grandjean E.M., Berthet P., Ruffmann R., and Leuenberger P. Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis. Pharmacol Res 42 (2000) 39-50
30. Andrus J.P., Herzenberg L.A., and DeRosa S.C. Effects of legislation restricting pack sizes of paracetamol on self poisoning. Paracetamol should be packaged with its antidote. BMJ 323 (2001) 634
31. Hazelton G.A., Hjelle J.J., and Klaassen C.D. Effects of cysteine pro-drugs on acetaminophen-induced hepatotoxicity. J Pharmacol Exp Ther 237 (1986) 341-349
32. Reid M., and Jahoor F. Glutathione in disease. Curr Opin Clin Nutr Metab Care 4 (2001) 65-71
33. Perl A., and Banki K. Genetic and metabolic control of the mitochondrial transmembrane potential and reactive oxygen intermediate production in HIV disease. Antioxid Redox Signal 2 (2000) 551-573
34. Spada C., Treitinger A., Reis M., Masokawa I.Y., Verdi J.C., Luiz M.C., Silveira M.V., Michelon C.M., Avila-Junior S., Gil D.O., et al. The effect of N-acetylcysteine supplementation upon viral load, CD4, CD8, total lymphocyte count and hematocrit in individuals undergoing antiretroviral treatment. Clin Chem Lab Med 40 (2002) 452-455
35. Estensen R.D., Levy M., Klopp S.J., Galbraith A.R., Mandel J.S., Blomquist J.A., and Wattenberg L.W. N-Acetylcysteine suppression of the proliferative index in the colon of patients with previous adenomatous colonic polyps. Cancer Lett 147 (1999) 109-114
36. Badaloo A., Reid M., Forrester T., Heird W.C., and Jahoor F. Cysteine supplementation improves the erythrocyte glutathione synthesis rate in children with severe edematous malnutrition. Am J Clin Nutr 76 (2002) 646-652
37. De Mattia G., Bravi M.C., Laurenti O., Cassone-Faldetta M., Proietti A., De Luca O., Armiento A., and Ferri C. Reduction of oxidative stress by oral N-acetyl-l-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes. Diabetologia 41 (1998) 1392-1396
38. Adair J.C., Knoefel J.E., and Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 57 (2001) 1515-1517
39. Parr G.D., and Huitson A. Oral fabrol (oral N-acetyl-cysteine) in chronic bronchitis. Br J Dis Chest 81 (1987) 341-348
40. Svendsen J.H., Klarlund K., Aldershvile J., and Waldorff S. N-Acetylcysteine modifies the acute effects of isosorbide-5-mononitrate in angina pectoris patients evaluated by exercise testing. J Cardiovasc Pharmacol 13 (1989) 320-323
41. Droge W., Eck H.P., and Mihm S. HIV-induced cysteine deficiency and T-cell dysfunction-a rationale for treatment with N-acetylcysteine. Immunol Today 13 (1992) 211-214
42. Herzenberg L.A., De Rosa S.C., Dubs J.G., Roederer M., Anderson M.T., Ela S.W., and Deresinski S.C. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci USA 94 (1997) 1967-1972
43. Stephensen C.B., Marquis G.S., Douglas S.D., Kruzich L.A., and Wilson C.M. Glutathione, glutathione peroxidase, and selenium status in HIV-positive and HIV-negative adolescents and young adults. Am J Clin Nutr 85 (2007) 173-181. This study shows that young well-nourished HIV patients have elevated GPx activity due to HIV-induced oxidative stress. However, no GSH deficiencies were detected in these patients.
44. Akerlund B., Jarstrand C., Lindeke B., Sonnerborg A., Akerblad A.-C., and Rasool O. Effect of N-acetylcysteine (NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. Eur J Clin Pharmacol 50 (1996) 457-461
45. Poole P.J., and Black P.N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 322 (2001) 1271-1274